Effective palliation of patients with incurable neuroendocrine tumors requires both control of hormonal overproduction symptoms as well as control of tumor growth. Several important advances have been made in recent years toward these two goals. Octreotide and omeprazole have both been extremely eff
Surgical treatment of gastrointestinal neuroendocrine tumors
β Scribed by Volker Fendrich; Detlef K. Bartsch
- Publisher
- Springer
- Year
- 2011
- Tongue
- English
- Weight
- 683 KB
- Volume
- 396
- Category
- Article
- ISSN
- 1435-2451
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The aggressiveness of poorly-differentiated neuroendocrine tumors is similar to small-cell lung cancer within a median survival of 6 months without treatment. Most patients have metastatic disease and poor condition at the time of diagnosis, and cannot be approached surgically with curative intent.
## BACKGROUND. Patients with neuroendocrine gastrointestinal tumors usually present with inoperable metastatic disease and severe hormonal symptoms. Specific chemotherapy, interferon-β£ (IFN), and somatostatin analogs are established therapies for these patients, but all of them eventually fail. Hep